Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03620474

Recruitment Status : Completed

First Posted : August 8, 2018

Last Update Posted : July 7, 2022

Sponsor:

Collaborators:

Prism Pharma Co., Ltd.

Kyushu University

National Center for Global Health and Medicine, Japan

Japan Agency for Medical Research and Development

Ohara Pharmaceutical Co., Ltd.

Information provided by (Responsible Party):

Kiminori Kimura, MD, Komagome Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	July 13, 2021
Actual Study Completion Date :	February 28, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine. 2022 Jun;80:104069. doi: 10.1016/j.ebiom.2022.104069. Epub 2022 May 20.

To Top